Results 91 to 100 of about 18,364 (184)

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, Volume 183, Issue 9, Page 1727-1746, May 2026.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

Sodium‐glucose co‐transporter 2 inhibitors and obesity‐associated cancers in people with type 2 diabetes: A real‐world observational study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3807-3818, May 2026.
Abstract Aims To investigate the association between sodium‐glucose co‐transporter 2 inhibitors (SGLT‐2i) and obesity‐associated cancers (OAC) in individuals with type 2 diabetes (T2D). Materials and Methods This retrospective cohort study used data from the TriNetX US Collaborative Network.
Testimony Ipaye, Jonathan Goldney, Thomas Yates, Francesco Zaccardi, Kamlesh Khunti, Elina Akalestou, Melanie J. Davies, Karen Brown, Dimitris Papamargaritis   +8 more
wiley   +1 more source

Uptake and early outcomes of a meal replacement intervention in an ethnically diverse adult population living with obesity and significant comorbidity

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3924-3932, May 2026.
Abstract Aims Structured meal replacement low energy diets (MR‐LED) are effective in obesity management, but evidence for individuals of minority ethnic groups or those with BMI >35 kg/m2 and significant comorbidities is limited. Materials and methods We evaluated the early effectiveness of a weight management program delivered by a multidisciplinary ...
James Shand, Naomi Brosnahan, Yannan Jiang, Rinki Murphy   +3 more
wiley   +1 more source

Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction‐Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4253-4260, May 2026.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is closely linked to obesity and insulin resistance, and sustained weight loss is associated with histological improvement. Whether different obesity‐management modalities exert weight‐independent hepatic effects remains uncertain.
Matteo Monami, Amanda Belluzzi, Silvio Buscemi, Luca Busetto, Ricardo Cohen, Maurizio De Luca, Andrea Galli, Edoardo Mannucci, Tarissa Z. Petry, Benedetta Ragghianti, Paolo Sbraccia, Dror Dicker   +11 more
wiley   +1 more source

RATIONALE FOR THE SELECTION OF AUXILIARY COMPONENTS FOR THE NALTREXONE HYDROCHLORIDE NASAL SPRAY

Разработка и регистрация лекарственных средств, 2019
The work is devoted to the development of nasal spray containing naltrexone hydrochloride. Naltrexone in doses of 3-5 mg/day acts on the opioid growth factor receptor (OGFr) and toll-like receptor 4 that makes it promising for use in the complex therapy ...
Y. M. Domnina, S. A. Kedik, V. V. Suslov, E. A. Shnyak   +3 more
doaj  

Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl‐induced respiratory depression at 3 months—A pilot study in male canines

Physiological Reports
The aim of this study is to determine if extended‐release, bioabsorbable, subcutaneous naltrexone (NTX) implants can mitigate respiratory depression after an intravenous injection (IV) of fentanyl. Six different BIOabsorbable Polymeric Implant Naltrexone
Robert L. Joyner, Joseph A. Hollenbaugh, Donald D'Aquila, Marc Fishman, Steven M. Cohen, Veera Holdai, Jeffrey D. Benner   +6 more
doaj   +1 more source

Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives

Patient Preference and Adherence, 2016
Cenk Tek Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA Abstract: Naltrexone, an opiate antagonist, and bupropion, a noradrenergic/dopaminergic antidepressant, have many effects on the reward systems of the brain.
Tek C
doaj  

Naltrexone treatment improves anxiety- and depression-like behavior in alcohol-exposed mice. [PDF]

Behav Pharmacol
Yang S, Tong L, Zhang L, Cui R, Lyu X, He L, Liu H.   +6 more
europepmc   +1 more source

Low-Dose Naltrexone in Chronic Pain Management: Mechanisms, Evidence, and Clinical Implications. [PDF]

J Pers Med
McKenzie A, Bittar T, Dombrower R, Raman D, Hussain H, Theeraphapphong N, McKenzie SM, Abd-Elsayed A.   +7 more
europepmc   +1 more source

Naltrexone/bupropion for binge-eating disorder: A human laboratory investigation of mechanisms. [PDF]

Drug Alcohol Depend Rep
McKee SA, Lydecker JA, Pittman B, Jastreboff AM, DiLeone RJ, Lavery M, Grilo CM.   +6 more
europepmc   +1 more source